Dipeptidyl Peptidase-4 Inhibitors Improved Lipid Levels in Patients With Type 2 Diabetes: A Meta-analysis of Randomized Clinical Trials.
Nutr RevSep 1, 2026
Clinical ResearchEndocrinology
Lijia Zhao, Jie Meng, Jingjing Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the effects of dipeptidyl peptidase-4 inhibitors (DPP-4i) on lipid levels in patients with type 2 diabetes (T2D). The analysis included data from 95 randomized controlled trials. DPP-4i significantly reduced low-density lipoprotein cholesterol (LDL-C) by 3.48 mg/dL, total cholesterol (TC) by 2.59 mg/dL, triglycerides (TG) by 5.39 mg/dL, and non-HDL-C by 6.27 mg/dL.
Key findings
- DPP-4i reduced LDL-C by 3.48 mg/dL (95% CI, -4.77 to -2.20).
- Total cholesterol decreased by 2.59 mg/dL (95% CI, -3.88 to -1.29).
- Triglycerides were reduced by 5.39 mg/dL (95% CI, -8.04 to -2.75).
- Non-HDL-C levels decreased by 6.27 mg/dL (95% CI, -10.94 to -1.60).
Why it matters
Improving lipid profiles in patients with type 2 diabetes can enhance cardiovascular health and reduce the risk of diabetes-related complications. This study highlights the additional benefits of DPP-4i beyond glycemic control.